Boston Scientific Co. (NYSE:BSX) EVP Sells $127,678.31 in Stock

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 1,201 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $106.31, for a total transaction of $127,678.31. Following the transaction, the executive vice president now directly owns 25,443 shares in the company, valued at $2,704,845.33. The trade was a 4.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

John Bradley Sorenson also recently made the following trade(s):

• On Tuesday, February 18th, John Bradley Sorenson sold 2,657 shares of Boston Scientific stock. The stock was sold at an average price of $104.41, for a total transaction of $277,417.37.
• On Wednesday, February 12th, John Bradley Sorenson sold 6,389 shares of Boston Scientific stock. The stock was sold at an average price of $105.06, for a total transaction of $671,228.34.
• On Friday, February 7th, John Bradley Sorenson sold 6,528 shares of Boston Scientific stock. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16.
• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The shares were sold at an average price of $90.02, for a total transaction of $370,792.38.

Boston Scientific Trading Up 0.3 %

Shares of NYSE:BSX opened at $105.63 on Thursday. The company has a market cap of $155.68 billion, a PE ratio of 84.50, a P/E/G ratio of 2.81 and a beta of 0.80. The company’s 50-day moving average price is $97.39 and its 200 day moving average price is $88.94. Boston Scientific Co. has a fifty-two week low of $65.33 and a fifty-two week high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Sell-side analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Institutional Trading of Boston Scientific

Several hedge funds have recently bought and sold shares of BSX. Norges Bank bought a new stake in shares of Boston Scientific during the 4th quarter worth about $1,762,522,000. Capital World Investors raised its position in shares of Boston Scientific by 28.7% during the 4th quarter. Capital World Investors now owns 27,899,903 shares of the medical equipment provider’s stock worth $2,492,041,000 after buying an additional 6,216,199 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Boston Scientific by 10.2% during the 4th quarter. Wellington Management Group LLP now owns 36,165,399 shares of the medical equipment provider’s stock worth $3,230,293,000 after buying an additional 3,344,571 shares in the last quarter. AustralianSuper Pty Ltd raised its position in shares of Boston Scientific by 4,292.3% during the 3rd quarter. AustralianSuper Pty Ltd now owns 2,676,847 shares of the medical equipment provider’s stock worth $224,320,000 after buying an additional 2,615,903 shares in the last quarter. Finally, Axiom Investors LLC DE raised its position in shares of Boston Scientific by 208.2% during the 4th quarter. Axiom Investors LLC DE now owns 3,752,430 shares of the medical equipment provider’s stock worth $335,167,000 after buying an additional 2,535,007 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BSX shares. TD Cowen raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. JPMorgan Chase & Co. raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Monday, December 16th. Morgan Stanley raised their price target on shares of Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Friday, January 10th. Finally, Citigroup raised their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. One investment analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $107.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.